The IMID Forum

Laura Coates takes you through our top picks from the selection of axial spondyloarthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!

Laura Coates takes you through our top picks from the selection of rheumatoid arthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!

EULAR 2022 Preview Podcast by The Immune-Mediated Inflammatory Disease Forum

Join Prof Iain McInnes as he reviews two interesting papers published in May 2022! The first – from Bartlett et al – looks at the impact of tofacitinib on fatigue, sleep and HRQoL in patients with RA. While the second assesses the impact of JAKi or abatacept on RA-interstitial lung disease. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Peter Taylor, from the University of Oxford in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Peter Taylor discusses pain control in early RA treated with baricitinib monotherapy.

Prof Iain McInnes reviews three papers this month!. The first – from Taylor et al – looks at pain control in early RA treated with baricitinib, the second investigates the immunogenicity of pneumococcal vaccination in patients with RA receiving upadacitinib and MTX, and the third paper is a perspective on regulatory changes in the wake of the ORAL SURVEILLANCE results. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Rüdiger Müller, Rheumazentrum Ostschweiz, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Rüdiger Müller discusses his paper on the impact of switching tofacitinib dose in patients with RA.

Discussing Rheumatology: March 2022 by The Immune-Mediated Inflammatory Disease Forum

Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleischmann discusses the long-term safety and efficacy of upadacitinib or adalimumab in patients with RA.

Prof Iain McInnes reviews two papers this month, both on tofacitinib. The first looks at CV outcomes from the STAR-RA study, the second is a post-hoc analysis of ORAL Sequel looking into tofacitinib dose switching. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

ACR1540 Ana Rita Cruz - Machado by The Immune-Mediated Inflammatory Disease Forum

ACR1087 Omar Alsaed by The Immune-Mediated Inflammatory Disease Forum

Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the ORAL Surveillance study into CV and cancer risks with tofacitinib in patients with RA.

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the clinical management of HZ in patients with RA or PsA receiving tofacitinib.

Prof Iain McInnes reviews two papers this month, and discusses the risk of herpes zoster (HZ) events in patients with RA treated with tofacitinib, as well as interstitial lung disease (ILD), an extra-articular manifestation of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Prof Iain McInnes reviews two papers this month, and discusses exposure-adjusted incidence rates of TEAEs and AESIs with filgotinib, as well as the efficacy and safety of tofacitinib in pJIA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the safety of filgotinib in patients with RA.

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the incidence and risk of herpes zoster in patients with RA receiving upadacitinib.

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Professor Atul Deodhar, professor of medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Atul Deodhar discusses his review on JAK-STAT signalling in spondyloarthritis and what that means for the use of JAK inhibitors for SpA treatment.

Prof Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active RA.

Grace Wright presents the Day 4 highlights of the key abstracts and posters presented at ACR 2021.

Professor Leonard Calabrese presents the Day 3 highlights of the key abstracts and posters presented at ACR 2021.

Grace Wright presents the Day 2 highlights of the key abstracts and posters presented at ACR 2021.

Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Prof Calabrese presents the Day 1 highlights of the key abstracts and posters presented at ACR 2021.

A preview of the latest research at ACR 2021. Prof Ritchlin highlights important abstracts in cytokine signalling at the upcoming ACR Convergence.

Paul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.

Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Kurt de Vlam, Professor of Rheumatology at UZ Leuven, Belgium. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor de Vlam assess the impact of baseline pain severity on pain response and the time to improvement in patients with PsA receiving tofacitinib.

Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology/Rheumatology, Biopharmaceutical Consultant at Stanford University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Strand discusses improvements in PROs in patients with RA treated with upadacitinib monotherapy.

Prof Iain McInnes discusses an essential part of the assessment of patients with rheumatic diseases; patient reported outcomes, or PROs. Improving PROs is crucial to effect tangible change in diseases and patient outcomes - to the extent that PROs are now included as an important component of many clinical trials. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Prof Iain McInnes discusses long-term data from the SELECT-PsA 2 study, and the impact of DMARDs on COVID-19 outcomes. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Philip Mease, Professor at the University of Washington School of Medicine in Seattle. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Mease discusses the longer-term safety and maintenance of efficacy of upadacitinib in patients with RA.

Jeffrey Sparks, from Brigham and Women's Hospital in Boston, and Zachary Wallace from the Massachusetts General Hospital. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Jeffery Sparks and Zachary Wallace discuss the latest results from the COVID-19 Global Rheumatology Alliance physician registry.

Francesco Ciccia, Assistant Professor of Rheumatology at the University of Palermo in Italy. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Ciccia discusses with Professor Nash the impact of pain in patients with rheumatic diseases and the physiological basis of modulating nociceptive pain, speculating that JAK inhibitors may have a dual therapeutic role.

Prof Iain McInnes discusses the main highlights of EULAR 2021 and the key takeaway messages. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Stanley Cohen, Clinical Professor in the Department of Internal Medicine and Co-Director of the Division of Rheumatology from the UT Southwestern Medical Center and Presbyterian Hospital, Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Cohen discusses radiographic progression in patients with RA treated with tofacitinib.

Dr Elena Nikiphorou presents the Day 4 highlights of the key abstracts and posters presented at EULAR 2021.

Professor Douglas Veale presents the Day 3 highlights of the key abstracts and posters presented at EULAR 2021.

Dr Elena Nikiphorou presents the Day 2 highlights of the key abstracts and posters presented at EULAR 2021.

Prof Veale presents the Day 1 highlights of the key abstracts and posters presented at EULAR 2021.

A preview of the latest research at EULAR 2021. Prof Edwards presents a preview of the upcoming EULAR 2021 congress, highlighting important abstracts and posters in cytokine signalling.